Laura Huppert, MD, BA
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Laura Huppert, MD, BA sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Laura Huppert, MD, BA: 3 sponsored US clinical trials, 2 recruiting.
Laura Huppert, MD, BA sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stage IIIC Breast Cancer, with 1 trials.
Upper-quartile sponsor footprint
Laura Huppert, MD, BA sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT06224673
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT03971409
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT03095352
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
What is open in the Laura Huppert, MD, BA pipeline
2 recruiting of 3 indexed (67% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Stage IIIC Breast Cancer (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Laura Huppert, MD, BA: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Laura Huppert, MD, BA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Laura Huppert, MD, BA page
3 registered trials is a research-attention snapshot, not an endorsement of Laura Huppert, MD, BA or any single study.
- 2 of Laura Huppert, MD, BA's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Stage IIIC Breast Cancer is the condition Laura Huppert, MD, BA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stage IIIC Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Laura Huppert, MD, BA pipeline card: 3 registered trials from official public datasets.Report a data error.